Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane

Regulatory Toxicology and Pharmacology

Volumn 50, Issue 2, 2008, Pages 249-260

  Lu, Yasong ^a   Rieth, Susan ^b   Lohitnavy, Manupat ^a   Dennison, James ^a   El Masri, Hisham ^c   Barton, Hugh A ^b   Bruckner, James ^d   Yang, Raymond S H ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

1,1,1 Trichloroethane; Extrapolation; Health risk assessment; Internal dose metric; PBPK modeling; Reference concentration (RfC); Reference dose (RfD)

Indexed keywords

1,1,1 TRICHLOROETHANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CHEMICAL MODEL; CONTROLLED STUDY; DOSIMETRY; EXPOSURE; HUMAN; HUMAN CELL; LIVER METABOLISM; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; PRIORITY JOURNAL; RAT; REFERENCE VALUE; SPECIES IDENTIFICATION; TOXICITY TESTING;

ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHALATION EXPOSURE; MICE; MICE, INBRED STRAINS; MODELS, STATISTICAL; RATS; RATS, INBRED F344; REFERENCE VALUES; RISK ASSESSMENT; SOLVENTS; TISSUE DISTRIBUTION; TRICHLOROETHANES; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

MUS; RATTUS;

EID: 39149129618     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2007.12.001     Document Type: Article

References (78)

1. Andersen M.E. Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol. Lett. 138 (2003) 9-27
2. Agency for Toxic Substances and Disease Registry (ATSDR), 2006. Toxicological Profile for 1,1,1-Trichloroethane. U.S. Department of Health and Human Services, Atlanta. http://www.atsdr.cdc.gov/toxprofiles/tp70.html Accessed August 1, 2007.
3. Bernillon P., and Bois F.Y. Statistical issues in toxicokinetic modeling: a bayesian perspective. Environ. Health Perspect. 108 Suppl 5 (2000) 883-893
4. Bogen K.T., and Hall L.C. Pharmacokinetics for regulatory risk analysis: the case of 1,1,1-trichloroethane (methyl chloroform). Regul. Toxicol. Pharmacol. 10 (1989) 26-50
5. Boyes W.K., Bushnell P.J., Crofton K.M., Evans M., and Simmons J.E. Neurotoxic and pharmacokinetic responses to trichloroethylene as a function of exposure scenario. Environ. Health Perspect. 108 Suppl 2 (2000) 317-322
6. Boyes W.K., Bercegeay M., Ali J.S., Krantz T., McGee J., Evans M., Raymer J.H., Bushnell P.J., and Simmons J.E. Dose-based duration adjustments for the effects of inhaled trichloroethylene on rat visual function. Toxicol. Sci. 76 (2003) 121-130
7. Boyes W.K., Evans M.V., Eklund C., Janssen P., and Simmons J.E. Duration adjustment of acute exposure guideline level values for trichloroethylene using a physiologically-based pharmacokinetic model. Risk Anal. 25 (2005) 677-686
8. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13 (1997) 407-484
9. Bruckner J.V., Kyle G.M., Luthra R., Acosta D., Mehta S.M., Sethuraman S., and Muralidhara S. Acute, short-term, and subchronic oral toxicity of 1,1,1-trichloroethane in rats. Toxicol. Sci. 60 (2001) 363-372
10. Bruckner J.V., Keys D.A., and Fisher J.W. The Acute Exposure Guideline Level (AEGL) program: applications of physiologically based pharmacokinetic modeling. J. Toxicol. Environ. Health A 67 (2004) 621-634
11. Bushnell P.J., Shafer T.J., Bale A.S., Boyes W.K., Simmons J.E., Eklund C., and Jackson T.L. Developing an exposure-dose-response model for the acute neurotoxicity of organic solvents: overview and progress on in vitro models and dosimetry. Environ. Tox. Pharmacol. 19 (2005) 607-614
12. Caperos J.R., Droz P.O., Hake C.L., Humbert B.E., and Jacot-Guillarmod A. 1,1,1-Trichloroethane exposure, biologic monitoring by breath and urine analyses. Int. Arch. Occup. Environ. Health 49 (1982) 293-303
13. Chiu W.A., and Bois F.Y. Revisiting the population toxicokinetics of tetrachloroethylene. Arch. Toxicol. 80 (2006) 382-385
14. Clewell III H.J., Lee T.S., and Carpenter R.L. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal. 14 (1994) 521-531
15. Clewell III H.J., Gentry P.R., Covington T.R., and Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 108 Suppl. 2 (2000) 283-305
16. Covington T.R., Gentry P.R., Van Landingham C.B., Andersen M.E., Kester J.E., and Clewell H.J. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul. Toxicol. Pharmacol. 47 (2007) 1-18
17. Dallas C.E., Ramanathan R., Muralidhara S., Gallo J.M., and Bruckner J.V. The uptake and elimination of 1,1,1-trichloroethane during and following inhalation exposures in rats. Toxicol. Appl. Pharmacol. 98 (1989) 385-397
18. David R.M., Clewell H.J., Gentry P.R., Covington T.R., Morgott D.A., and Marino D.J. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul. Toxicol. Pharmacol. 45 (2006) 55-65
19. De Ceaurriz J., Desiles J.P., Bonnet P., Marignac B., Muller J., and Guenier J.P. Concentration-dependent behavioral changes in mice following short-term inhalation exposure to various industrial solvents. Toxicol. Appl. Pharmacol. 67 (1983) 383-389
20. DeJongh J., Verhaar H.J., and Hermens J.L. Role of kinetics in acute lethality of nonreactive volatile organic compounds (VOCs). Toxicol. Sci. 45 (1998) 26-32
21. DeWoskin R.S., Lipscomb J.C., Thompson C., Chiu W.A., Schlosser P., Smallwood C., Swartout J., Teuschler L., and Marcus A. Pharmacokinetic/physiologically based pharmacokinetic models in integrated risk information system assessments. In: Lipscomb J.C., and Ohanian E.V. (Eds). Toxicokinetics and Risk Assessment (2007), Informa Healthcare, NY 301-348
22. Dobrev I.D., Andersen M.E., and Yang R.S. Assessing interaction thresholds for trichloroethylene in combination with tetrachloroethylene and 1,1,1-trichloroethane using gas uptake studies and PBPK modeling. Arch. Toxicol. 75 (2001) 134-144
23. Dobrev I.D., Andersen M.E., and Yang R.S. In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane. Environ. Health Perspect. 110 (2002) 1031-1039
24. Doherty R.E. A history of the production and use of carbon tetrachloride, tetrachloroethylene, trichloroethylene and 1,1,1-trichloroethane in the United States. Part 2: Trichloroethylene and 1,1,1-trichloroethane. J. Environ. Forensics 1 (2000) 83-93
25. Droz P.O., Wu M.M., Cumberland W.G., and Berode M. Variability in biological monitoring of solvent exposure. I Development of a population physiological model. Br. J. Ind. Med. 46 (1989) 447-460
26. Gamberale F., and Hultengren M. Methylchloroform exposure. II. Psychophysiological functions. Work Environ. Health 10 (1973) 82-92
27. Gargas M.L., Andersen M.E., and Clewell III H.J. A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicol. Appl. Pharmacol. 86 (1986) 341-352
28. Gargas M.L., Burgess R.J., Voisard D.E., Cason G.H., and Andersen M.E. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 98 (1989) 87-99
29. Jonsson F., and Johanson G. The Bayesian population approach to physiological toxicokinetic-toxicodynamic models-an example using the MCSim software. Toxicol. Lett. 138 (2003) 143-150
30. Katagiri H., Aoki N., Soma K., Karube H., Aizawa Y., Kadowaki T., and Inoue Y. Concentration in blood and organs of dogs after high dose 1,1,1-trichloroethane inhalation. Ind. Health 35 (1997) 461-466
31. Kezic S., Monster A.C., Kruse J., and Verberk M.M. Skin absorption of some vaporous solvents in volunteers. Int. Arch. Occup. Environ. Health 73 (2000) 415-422
32. Kim A.H., Kohn M.C., Portier C.J., and Walker N.J. Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses. Regul. Toxicol. Pharmacol. 36 (2002) 287-296
33. Kinkead E.R., and Wolfe R.E. Single oral toxicity of various organic compounds. J. Am. Coll. Toxicol. 11 (1992) 713
34. Kobayashi H., Hobara T., Kawamoto T., and Sakai T. Effect of 1,1,1-trichloroethane inhalation on heart rate and its mechanism: a role of autonomic nervous system. Arch. Environ. Health 42 (1987) 140-143
35. Krishnan K., and Johanson G. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 23 (2005) 31-53
36. Krol M.C., Lelieveld J., Oram D.E., Sturrock G.A., Penkett S.A., Brenninkmeijer C.A., Gros V., Williams J., and Scheeren H.A. Continuing emissions of methyl chloroform from Europe. Nature 421 (2003) 131-135
37. Lapare S., Tardif R., and Brodeur J. Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. II. 1,1,1-Trichloroethane and trichloroethylene. Int. Arch. Occup. Environ. Health 67 (1995) 375-394
38. Leung H.W. Use of physiologically based pharmacokinetic models to establish biological exposure indexes. Am. Ind. Hyg. Assoc. J. 53 (1992) 369-374
39. Levitt K.G. Heterogeneity of human adipose blood flow. BMC Clin. Pharm. 7 (2007) 1-21
40. Loizou G.D., Eldirdiri N.I., and King L.J. Physiologically based pharmacokinetics of uptake by inhalation of a series of 1,1,1-trihaloethanes: correlation with various physiochemical parameters. Inhal. Toxicol. 8 (1996) 1-19
41. Lu Y., Lohitnavy M., Reddy M.B., Lohitnavy O., and Yang R.S.H. An updated physiologically based pharmacokinetic modeling of hexachlorobenzene: incorporation of pathophysiological states following partial hepatectomy and hexachlorobenzene treatment. Toxicol. Sci. 91 (2006) 29-41
42. Mackay C.J., Campbell L., Samuel A.M., Alderman K.J., Idzikowski C., Wilson H.K., and Gompertz D. Behavioral changes during exposure to 1,1,1-trichloroethane: time-course and relationship to blood solvent levels. Am. J. Ind. Med. 11 (1987) 223-239
43. Marino D.J., Clewell H.J., Gentry P.R., Covington T.R., Hack C.E., David R.M., and Morgott D.A. Revised assessment of cancer risk to dichloromethane: Part I Bayesian PBPK and dose-response modeling in mice. Regul. Toxicol. Pharmacol. 45 (2006) 44-54
44. McNutt N.S., Amster R.L., McConnell E.E., and Morris F. Hepatic lesions in mice after continuous inhalation exposure to 1,1,1-trichloroethane. Lab. Invest. 32 (1975) 642-654
45. Monster A.C., Boersma G., and Steenweg H. Kinetics of 1,1,1-trichloroethane in volunteers; influence of exposure concentration and work load. Int. Arch. Occup. Environ. Health 42 (1979) 293-301
46. Nolan R.J., Freshour N.L., Rick D.L., McCarty L.P., and Saunders J.H. Kinetics and metabolism of inhaled methyl chloroform (1,1,1-trichloroethane) in male volunteers. Fundam. Appl. Toxicol. 4 (1984) 654-662
47. National Toxicology Program (NTP), 2000. NTP Technical Report on the Toxicity Studies of 1,1,1-Trichloroethane (CAS No.71-55-6) Administered in Microcapsules in Feed to F344/N Rats and B6C3F1 Mice. Public Health Service, U.S. Department of Health and Human Services, NTP Toxicity Report Series No. 41. http://ntp.niehs.nih.gov/ntp/htdocs/ST_rpts/tox041.pdf Accessed August 1, 2007.
48. Oak Ridge National Laboratory (ORNL), 2000. Interim acute exposure guideline levels (AEGLs): 1,1,1-Trichloroethane CAS Reg. No. 71-55-06. Oak Ridge, TN. Prepared for the NAS/COT Subcommittee for AEGLs. June. http://www.epa.gov/oppt/aegl/pubs/tsd203.pdf Accessed August 1, 2007.
49. Poet T.S., Thrall K.D., Corley R.A., Hui X., Edwards J.A., Weitz K.K., Maibach H.I., and Wester R.C. Utility of real time breath analysis and physiologically based pharmacokinetic modeling to determine the percutaneous absorption of methyl chloroform in rats and humans. Toxicol. Sci. 54 (2000) 42-51
50. Quast J.F., Calhoun L.L., and Frauson L.E. 1,1,1-Trichloroethane formulation: a chronic inhalation toxicity and oncogenicity study in Fischer 344 rats and B6C3F1 mice. Fund. Appl. Toxicol. 11 (1988) 611-625
51. Ramsey J.C., and Andersen M.E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73 (1984) 159-175
52. Reddy M., Yang R.S.H., Clewell III H.J., and Andersen M.E. Physiologically Based Pharmacokinetics: Science and Applications (2005), John Wiley & Sons, Hoboken, NJ pp. 420
53. Reinhardt C.F., Mullin L.S., and Maxfield M.E. Epinephrine-induced cardiac arrhythmia potential of some common industrial solvents. J. Occup. Med. 15 (1973) 953-955
54. Reisfeld B., Mayeno A.N., Lyons M.A., and Yang R.S.H. Physiologically-based pharmacokinetic and pharmacodynamic modeling. In: Ekins S. (Ed). Computational Toxicology. Risk Assessment for Pharmaceutical and Environmental Chemicals (2007), John Wiley & Sons, Hoboken, NJ 33-69
55. Reitz R.H., Nolan R.J., and Schumann A.M. Development of multispecies, multiroute pharmacokinetic models for methylene chloride and 1,1,1-trichloroethane (methyl chloroform). In: Thomas R.D. (Ed). Drinking Water and Health vol. 8 (1987), Springer, Washington, DC 391-409
56. Reitz R.H., McDougal J.N., Himmelstein M.W., Nolan R.J., and Schumann A.M. Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations. Toxicol. Appl. Pharmacol. 95 (1988) 185-199
57. Reitz R.H., Gargas M.L., Andersen M.E., Provan W.M., and Green T.L. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. Toxicol. Appl. Pharmacol. 137 (1996) 253-267
58. Savolainen K., Riihimaki V., Laine A., and Kekoni J. Short-term exposure of human subjects to m-xylene and 1,1,1-trichloroethane. Int. Arch. Occup. Environ. Health 49 (1981) 89-98
59. Savolainen K., Riihimaki V., and Laine A. Biphasic effects of inhaled solvents on human equilibrium. Acta Pharmacol. Toxicol. (Copenh) 51 (1982) 237-242
60. Savolainen K., Riihimaki V., Laine A., and Kekoni J. Short-term exposure of human subjects to m-xylene and 1,1,1-trichloroethane. Arch. Toxicol. Suppl. 5 (1982) 96-99
61. Schumann A.M., Fox T.R., and Watanabe P.G. [14C]Methyl chloroform (1,1,1-trichloroethane): pharmacokinetics in rats and mice following inhalation exposure. Toxicol. Appl. Pharmacol. 62 (1982) 390-401
62. Sielken Jr. R.L., Reitz R.H., and Hays S.M. Using PBPK modeling and comprehensive realism methodology for the quantitative cancer risk assessment of butadiene. Toxicology 113 (1996) 231-237
63. Simmons J.E., Evans M.V., and Boyes W.K. Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose. J. Toxicol. Environ. Health A 68 (2005) 927-950
64. Tardif R., and Charest-Tardif G. The importance of measured end-points in demonstrating the occurrence of interactions: a case study with methylchloroform and m-xylene. Toxicol. Sci. 49 (1999) 312-317
65. Torkelson T.R., Oyen F., McCollister D.D., et al. Toxicity of 1,1,1-trichloroethane as determined on laboratory animals and human subjects. Am. Ind. Hyg. Assoc. J. 19 (1958) 353-362
66. United Nations Environment Programme (UNEP), 2000. The Montreal Protocol on substances that deplete the ozone layer as adjusted and/or amended in London 1990, Copenhagen 1992, Vienna 1995, Montreal 1997, Beijing 1999, Ozone Secretariat, United Nations Environment Programme.
67. U.S. Environmental Protection Agency (U.S. EPA), 2005. Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment (Final report). Washington, DC, EPA/600/R-05/043A.
68. U.S. Environmental Protection Agency (U.S. EPA), 2007. 1,1,1-Trichloroethane. Integrated risk information system (IRIS). National Center for Environmental Assessment, Washington, DC. http://www.epa.gov/iris Accessed September 28, 2007.
69. Walum E. Acute oral toxicity. Environ. Health Perspect. 106 Suppl. 2 (1998) 497-503
70. Warren D.A., Reigle T.G., Muralidhara S., and Dallas C.E. Schedule-controlled operant behavior of rats during 1,1,1-trichloroethane inhalation: relationship to blood and brain solvent concentrations. Neurotoxicol. Teratol. 20 (1998) 143-153
71. Warren D.A., Bowen S.E., Jennings W.B., Dallas C.E., and Balster R.L. Biphasic effects of 1,1,1-trichloroethane on the locomotor activity of mice: relationship to blood and brain solvent concentrations. Toxicol. Sci. 56 (2000) 365-373
72. White, C.A., Muralidhara, S., Hines, C., Bruckner, J.V., submitted for publication-a. Effect of oral dosage regimen and rate on the bioavailability and metabolism of trichloroethylene and 1,1,1-trichloroethane. Drug Metab. Disp.
73. White, C.A., Dallas, C.E., Muralidhara, S., Hines, C., Bruckner, J.V., submitted for publication-b. Pharmacokinetics of inhaled 1,1,1-trichloroethane in rats. Toxicol. Sci.
74. Yang, R.S.H., 2006. Final Report for Physiologically Based Pharmacokinetic Modeling of 1,1,1-Trichloroethane (Project 04-10) ORISE Subcontract 5-10329. http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=56429 Accessed July 5, 2007.
75. Yang R.S.H., and Andersen M.E. Pharmacokinetics. In: Hodgson E., and Levi P. (Eds). Introduction to Biochemical Toxicology. 2nd ed. (1994), Appleton & Lange, East Norwalk, Connecticut
76. Yang R.S.H., and Lu Y. The application of physiologically based pharmacokinetic (PBPK) modeling to risk assessment. In: Robson M.G., and Toscano W.A. (Eds). Risk Assessment for Environmental Health (2007), John Wiley & Sons, Hoboken, NJ 85-120
77. Yoshida K. Preliminary exposure assessment of volatile chlorinated hydrocarbons in Japan. Chemosphere 27 (1993) 621-630
78. You L., and Dallas C.E. Regional brain dosimetry of trichloroethane in mice and rats following inhalation exposures. J. Toxicol. Environ. Health A 54 (1998) 285-299